Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 635472, 9 pages
http://dx.doi.org/10.1155/2012/635472
Review Article

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

1Institute for Clinical Research and Development, 55116 Mainz, Germany
2First Medical Department, Johannes Gutenberg University, Mainz, Germany

Received 4 January 2012; Accepted 6 February 2012

Academic Editor: Matteo Monami

Copyright © 2012 Thomas Forst et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Juutilainen, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects,” Diabetes Care, vol. 28, no. 12, pp. 2901–2907, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Whiteley, S. Padmanabhan, D. Hole, and C. Isles, “Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey,” Diabetes Care, vol. 28, no. 7, pp. 1588–1593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Calles-Escandon and M. Cipolla, “Diabetes and endothelial dysfunction: a clinical perspective,” Endocrine Reviews, vol. 22, no. 1, pp. 36–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Forst, C. Hohberg, and A. Pfützner, “Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients,” Hormone and Metabolic Research, vol. 41, no. 2, pp. 123–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Cosson, I. Pham, P. Valensi, J. Pariès, J. R. Attali, and A. Nitenberg, “Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries,” Diabetes Care, vol. 29, no. 1, pp. 107–112, 2006. View at Google Scholar · View at Scopus
  8. T. K. Schramm, G. H. Gislason, L. Køber et al., “Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people,” Circulation, vol. 117, no. 15, pp. 1945–1954, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. T. Friedewald, J. B. Buse, J. T. Bigger et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma, “Adipokines: molecular links between obesity and atheroslcerosis,” American Journal of Physiology, vol. 288, no. 5, pp. H2031–H2041, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Klöting, M. Fasshauer, A. Dietrich et al., “Insulin-sensitive obesity,” American Journal of Physiology, vol. 299, no. 3, pp. E506–E515, 2010. View at Publisher · View at Google Scholar
  14. F. B. Hu, M. J. Stampfer, S. M. Haffner, C. G. Solomon, W. C. Willett, and J. E. Manson, “Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes,” Diabetes Care, vol. 25, no. 7, pp. 1129–1134, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ishizaka, Y. Ishizaka, E. Takahashi et al., “Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 295–301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. G. M. Reaven, “Insulin resistance, the insulin resistance syndrome, and cardiovascular disease,” Panminerva Medica, vol. 47, no. 4, pp. 201–210, 2005. View at Google Scholar · View at Scopus
  17. K. J. Ausk, E. J. Boyko, and G. N. Ioannou, “Insulin resistance predicts mortality in nondiabetic individuals in the U.S,” Diabetes Care, vol. 33, no. 6, pp. 1179–1185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. C. McGill Jr., C. A. McMahan, E. E. Herderick et al., “Obesity accelerates the progression of coronary atherosclerosis in young men,” Circulation, vol. 105, no. 23, pp. 2712–2718, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Cho, J. E. Manson, M. J. Stampfer et al., “A prospective study of obesity and risk of coronary heart disease among diabetic women,” Diabetes Care, vol. 25, no. 7, pp. 1142–1148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Cauchi, S. D. Guerra, H. Choquet et al., “Meta-analysis and functional effects of the SLC30A8 rs13266634 polymorphism on isolated human pancreatic islets,” Molecular Genetics and Metabolism, vol. 100, no. 1, pp. 77–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Fritsche, A. Madaus, N. Stefan et al., “Relationships among age, proinsulin conversion, and β-cell function in nondiabetic humans,” Diabetes, vol. 51, supplement 1, pp. S234–S239, 2002. View at Google Scholar · View at Scopus
  22. K. Kirchhoff, F. Machicao, A. Haupt et al., “Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion,” Diabetologia, vol. 51, no. 4, pp. 597–601, 2008. View at Publisher · View at Google Scholar
  23. M. Alssema, J. M. Dekker, G. Nijpels, C. D. A. Stehouwer, L. M. Bouter, and R. J. Heine, “Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn study,” Diabetes Care, vol. 28, no. 4, pp. 860–865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Y. Oh, E. Barrett-Connor, and N. M. Wedick, “Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo study,” Circulation, vol. 105, no. 11, pp. 1311–1316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Wohlin, J. Sundström, J. Ärnlöv, B. Andrén, B. Zethelius, and L. Lind, “Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men,” Atherosclerosis, vol. 170, no. 1, pp. 181–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Zethelius, H. Lithell, C. N. Hales, and C. Berne, “Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp,” Diabetologia, vol. 48, no. 5, pp. 862–867, 2005. View at Publisher · View at Google Scholar
  27. B. Zethelius, L. Byberg, C. N. Hales, H. Lithell, and C. Berne, “Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study,” Circulation, vol. 105, no. 18, pp. 2153–2158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Galloway, S. A. Hooper, C. T. Spradlin et al., “Biosynthetic human proinsulin: review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience,” Diabetes Care, vol. 15, no. 5, pp. 666–692, 1992. View at Google Scholar · View at Scopus
  29. E. Z. Jia, Z. J. Yang, T. B. Zhu et al., “Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis,” Cardiology, vol. 110, no. 2, pp. 106–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. T. K. Nordt, D. J. Schneider, and B. E. Sobel, “Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease,” Circulation, vol. 89, no. 1, pp. 321–330, 1994. View at Google Scholar · View at Scopus
  31. H. Liu, A. E. Dear, L. B. Knudsen, and R. W. Simpson, “A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules,” Journal of Endocrinology, vol. 201, no. 1, pp. 59–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. K. Nordt, C. Bode, and B. E. Sobel, “Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin,” Diabetologia, vol. 44, no. 9, pp. 1121–1124, 2001. View at Publisher · View at Google Scholar
  33. A. Festa, R. D'Agostino Jr., L. Mykkänen et al., “Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS),” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 562–568, 1999. View at Google Scholar
  34. C. J. Lyon and W. A. Hsueh, “Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease,” American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 62S–68S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Forst, C. Hohberg, S. D. Fuellert et al., “Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes,” Hormone and Metabolic Research, vol. 37, no. 8, pp. 521–527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Verma and T. J. Anderson, “Fundamentals of endothelial function for the clinical cardiologist,” Circulation, vol. 105, no. 5, pp. 546–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. A. B. Goldfine, J. A. Beckman, R. A. Betensky et al., “Family history of diabetes is a major determinant of endothelial function,” Journal of the American College of Cardiology, vol. 47, no. 12, pp. 2456–2461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Mather, T. J. Anderson, and S. Verma, “Insulin action in the vasculature: physiology and pathophysiology,” Journal of Vascular Research, vol. 38, no. 5, pp. 415–422, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. D. J. Margolis, O. Hoffstad, and B. L. Strom, “Association between serious ischemic cardiac outcomes and medications used to treat diabetes,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 8, pp. 753–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. D. T. Eurich, F. A. McAlister, D. F. Blackburn et al., “Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review,” British Medical Journal, vol. 335, no. 7618, pp. 497–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca, “Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all- cause mortality?” Diabetes Care, vol. 31, no. 8, pp. 1672–1678, 2008. View at Publisher · View at Google Scholar
  43. S. Bolen, L. Feldman, J. Vassy et al., “Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus,” Annals of Internal Medicine, vol. 147, no. 6, pp. 386–399, 2007. View at Google Scholar · View at Scopus
  44. M. J. Davies, “Insulin secretagogues,” Current Medical Research and Opinion, vol. 18, supplement 1, pp. s22–s30, 2002. View at Google Scholar · View at Scopus
  45. T. J. Kieffer and J. F. Habener, “The glucagon-like peptides,” Endocrine Reviews, vol. 20, no. 6, pp. 876–913, 1999. View at Google Scholar · View at Scopus
  46. T. Matsuyama, R. Komatsu, M. Namba, N. Watanabe, H. Itoh, and S. Tarui, “Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone,” Diabetes Research and Clinical Practice, vol. 5, no. 4, pp. 281–284, 1988. View at Google Scholar · View at Scopus
  47. G. C. Weir, S. Mojsov, G. K. Hendrick, and J. F. Habener, “Glucagonlike peptide I (7-37) actions on endocrine pancreas,” Diabetes, vol. 38, no. 3, pp. 338–342, 1989. View at Google Scholar · View at Scopus
  48. A. Wettergren, B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christiansen, and J. J. Holst, “Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man,” Digestive Diseases and Sciences, vol. 38, no. 4, pp. 665–673, 1993. View at Google Scholar · View at Scopus
  49. M. A. Nauck, M. M. Heimesaat, C. Orskov, J. J. Holst, R. Ebert, and W. Creutzfeldt, “Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type- 2 diabetes mellitus,” The Journal of Clinical Investigation, vol. 91, no. 1, pp. 301–307, 1993. View at Google Scholar · View at Scopus
  50. M. H. Davidson, “Cardiovascular effects of glucagonlike peptide-1 agonists,” American Journal of Cardiology, vol. 108, no. 3, supplement, pp. 33B–41B, 2011. View at Publisher · View at Google Scholar
  51. J. Jendle, M. A. Nauck, D. R. Matthews et al., “Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue,” Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1163–1172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. C. Bunck, M. Diamant, B. Eliasson et al., “Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition,” Diabetes Care, vol. 33, no. 8, pp. 1734–1737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. D. D. Mafong and R. R. Henry, “The role of incretins in cardiovascular control,” Current Hypertension Reports, vol. 11, no. 1, pp. 18–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. D. C. Klonoff, J. B. Buse, L. L. Nielsen et al., “Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 275–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Marre, J. Shaw, M. Brändle et al., “Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU),” Diabetic Medicine, vol. 26, no. 3, pp. 268–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. B. Buse, J. Rosenstock, G. Sesti et al., “Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6),” The Lancet, vol. 374, no. 9683, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Okerson, P. Yan, A. Stonehouse, and R. Brodows, “Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes,” American Journal of Hypertension, vol. 23, no. 3, pp. 334–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S. S. Bolz, D. J. Drucker, and M. Husain, “Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways,” Circulation, vol. 117, no. 18, pp. 2340–2350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. J. P. Gutzwiller, S. Tschopp, A. Bock et al., “Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men,” The The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 3055–3061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. R. J. F. Loos, P. W. Franks, R. W. Francis et al., “TCF7L2 polymorphisms modulate proinsulin levels and β-cell function in a British europid population,” Diabetes, vol. 56, no. 7, pp. 1943–1947, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Stumvoll, A. Fritsche, N. Stefan, E. Hardt, and H. Häring, “Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and β-cell dysfunction,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 1235–1239, 2001. View at Publisher · View at Google Scholar
  62. T. Vilsbøll, B. Brock, H. Perrild et al., “Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus,” Diabetic Medicine, vol. 25, no. 2, pp. 152–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron, “Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2,” Diabetes Care, vol. 28, no. 5, pp. 1092–1100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Del Prato, A. H. Barnett, H. Huisman, D. Neubacher, H.-J. Woerle, and K. A. Dugi, “Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial,” Diabetes, Obesity and Metabolism, vol. 13, no. 3, pp. 258–267, 2011. View at Publisher · View at Google Scholar
  65. R. E. Pratley, A. Schweizer, J. Rosenstock et al., “Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database,” Diabetes, Obesity and Metabolism, vol. 10, no. 10, pp. 931–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami, “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus,” Diabetologia, vol. 49, no. 11, pp. 2564–2571, 2006. View at Publisher · View at Google Scholar
  67. S. Pscherer, M. Larbig, B. von Stritsky et al., “In type 2 diabetic patients, insulin glargine is associated with lower postprandial release of intact compared with sulfonyurea treatment,” Journal of Diabetes Science and Technology. In press.
  68. T. Forst, G. Michelson, F. Ratter et al., “Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function,” Diabetic Medicine. In press.
  69. K. Ban, S. Hui, D. J. Drucker, and M. Husain, “Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies,” Journal of the American Society of Hypertension, vol. 3, no. 4, pp. 245–259, 2009. View at Publisher · View at Google Scholar
  70. S. M. Gardiner, J. E. March, P. A. Kemp, T. Bennett, and D. J. Baker, “Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats,” British Journal of Pharmacology, vol. 161, no. 1, pp. 92–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Tomas and J. F. Habener, “Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis,” Trends in Endocrinology and Metabolism, vol. 21, no. 2, pp. 59–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. L. A. Nikolaidis, S. Mankad, G. G. Sokos et al., “Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion,” Circulation, vol. 109, no. 8, pp. 962–965, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. G. G. Sokos, L. A. Nikolaidis, S. Mankad, D. Elahi, and R. P. Shannon, “Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure,” Journal of Cardiac Failure, vol. 12, no. 9, pp. 694–699, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. J. P. Courrèges, T. Vilsbøll, M. Zdravkovic et al., “Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes,” Diabetic Medicine, vol. 25, no. 9, pp. 1129–1131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. R. M. Bergenstal, C. Wysham, L. MacConell et al., “Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial,” The Lancet, vol. 376, no. 9739, pp. 431–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. A. Golpon, A. Puechner, T. Welte, P. V. Wichert, and C. O. Feddersen, “Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat,” Regulatory Peptides, vol. 102, no. 2-3, pp. 81–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Richter, O. Feddersen, U. Wagner, P. Barth, R. Goke, and B. Goke, “GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery,” American Journal of Physiology, vol. 265, no. 4, pp. L374–L381, 1993. View at Google Scholar · View at Scopus
  78. A. Basu, N. Charkoudian, W. Schrage, R. A. Rizza, R. Basu, and M. J. Joyner, “Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride,” American Journal of Physiology, vol. 293, no. 5, pp. E1289–E1295, 2007. View at Publisher · View at Google Scholar
  79. Y. Hattori, T. Jojima, A. Tomizawa et al., “A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells,” Diabetologia, vol. 53, no. 10, pp. 2256–2263, 2010. View at Publisher · View at Google Scholar
  80. H. Liu, Y. Hu, R. W. Simpson, and A. E. Dear, “Glucagon-like peptide-1 attenuates tumour necrosis factor-α-mediated induction of plasmogen activator inhibitor-1 expression,” Journal of Endocrinology, vol. 196, no. 1, pp. 57–65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Nyström, M. K. Gutniak, Q. Zhang et al., “Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease,” American Journal of Physiology, vol. 287, no. 6, pp. E1209–E1215, 2004. View at Publisher · View at Google Scholar
  82. T. Vilsbøll, M. Zdravkovic, T. Le-Thi et al., “Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes,” Diabetes Care, vol. 30, no. 6, pp. 1608–1610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. S. M. Nicholl, E. Roztocil, and M. G. Davies, “Plasminogen activator system and vascular disease,” Current Vascular Pharmacology, vol. 4, no. 2, pp. 101–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Plutzky, A. J. Garber, A. Falahati et al., “The once daily human GLP-1-analogue, liraglutide significantly reduces markers of cardiovascular risk in type 2 diabetes: a metaanalysis of six clinical trials,” European Heart Journal, vol. 30, pp. 917–919, 2009. View at Google Scholar
  85. M. Arakawa, T. Mita, K. Azuma et al., “Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4,” Diabetes, vol. 59, no. 4, pp. 1030–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. B. Zilversmit, “Atherogenesis: a postprandial phenomenon,” Circulation, vol. 60, no. 3, pp. 473–485, 1979. View at Google Scholar · View at Scopus
  87. J. Koska, E. A. Schwartz, M. P. Mullin, D. C. Schwenke, and P. D. Reaven, “Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes,” Diabetes Care, vol. 33, no. 5, pp. 1028–1030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Ceriello, K. Esposito, R. Testa, A. R. Bonfigli, M. Marra, and D. Giugliano, “The possible protective role of glucagon-like peptide1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes,” Diabetes Care, vol. 34, no. 3, pp. 697–702, 2011. View at Publisher · View at Google Scholar
  89. J. H. Best, B. J. Hoogwerf, W. H. Herman et al., “Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the Glucagon-Like Peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database,” Diabetes Care, vol. 34, no. 1, pp. 90–95, 2011. View at Publisher · View at Google Scholar
  90. M. Monami, F. Cremasco, C. Lamanna et al., “Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials,” Experimental Diabetes Research, vol. 2011, Article ID 215764, 10 pages, 2011. View at Publisher · View at Google Scholar